Skip to main content
Equibles
VXRT logo

VXRT · Vaxart, Inc. · Metrics

Track VXRT — free

Use VXRT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VXRT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.32 +0.00 (+0.00%) At close · Jul 8 Play latest call Q4 2025 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Nov 5, 2026

Substantial doubt about the company's ability to continue as a going concern.

“In the second quarter of 2026, management concluded that our cash, cash equivalents and investments are not sufficient to fund our planned operations for at least twelve months from the date of issuance of our financial statements, and these conditions raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Nov 5, 2026
Market Cap
$126.27M
Shares
243.70M
Volume · Jul 8 11.57M Avg daily vol (3M) 4.77M

VXRT metrics

62 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.32
Market cap
$126.27M

Price action

23 metrics
Price change (1W)
-30.4%
Price change (30D)
—
Price change (3M)
+3.2%
Price change (6M)
-63.6%
Price change (YTD)
-51.5%
Price change (1Y)
-48.4%
Trailing year
Price change (5Y)
—
52-week high
$0.99
52-week low
$0.31
Change from 52-week high
-67.7%
Change from 52-week low
+3.2%
Annualized volatility
105.8%
Annualized volatility (3M)
137.6%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
31.5
Price vs SMA 50
-30.9%
Price vs SMA 200
-46.4%
Avg volume (3M)
4.77M
Relative volume
2.4
Average dollar volume
$2.29M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
243.70M

Valuation

12 metrics
P / E (TTM)
4.3
Trailing earnings · reciprocal yield 23.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.7×
reciprocal yield 143.6%
P / book
1.9
reciprocal yield 52.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
3.8
reciprocal yield 26.0%
Earnings yield
23.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
—
Operating margin
16.6%
Trailing 12 months
Net margin
16.0%
Gross profit (TTM)
−$25.20M
Operating profit (TTM)
$30.14M
Net income (TTM)
$29.04M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
2.4%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
$-0.65
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.37

Growth

11 metrics
Revenue growth YoY
-85.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$181.27M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+6.3%
Year over year · more shares
Revenue CAGR (3Y)
+1,204.0%
Revenue CAGR (5Y)
+125.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
43.8%
Return on assets
19.6%
Debt / equity
—
Current ratio
1.7
EBITDA (TTM)
$35.34M
Free cash flow (TTM)
—
Quick ratio
1.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$35.12M
Total assets
$148.18M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$32.82M
Capital expenditures (TTM)
$855,000
R&D (TTM)
$131.15M
SG&A (TTM)
—
Stock compensation (TTM)
$5.68M
R&D / revenue
72.3%
Stock compensation / revenue
3.1%

Ownership (13F)

9 metrics
13F filers
4
13F filer change QoQ
-1
Institutional ownership
0.0%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+14.0%
Holder tenure
19.7
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 72444 CUSIP 92243A200 13F (30d) 17 filings 6 filers Visit website Investor relations